Oxandrolone
drug drugOn this page
Also known as AnavarLonavarNSC-67068OxandrinOxandrolonaOxandrolone ciiiProvitarSC 11585SC-11585Vasorome
Summary
Oxandrolone (CHEMBL1200436) is an approved small-molecule anabolic agent (ATC A14AA08); indicated across 9 conditions including neoplasm and decubitus ulcer.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: A14AA08
- Indications: 9 conditions
- Clinical trials: 20
- Chemistry: 306.4 Da · C19H30O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200436 |
| Name | Oxandrolone |
| Type | Small molecule |
| Max phase | 4 |
| FDA approved | yes |
| PubChem CID | 5878 |
| ChEBI | CHEBI:7820 |
| ATC | A14AA08 |
| Molecular formula | C19H30O3 |
| Molecular weight | 306.4 |
| InChIKey | QSLJIVKCVHQPLV-PEMPUTJUSA-N |
SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C
IUPAC name: (1S,3aS,3bR,5aS,9aS,9bS,11aS)-1-hydroxy-1,9a,11a-trimethyl-2,3,3a,3b,4,5,5a,6,9,9b,10,11-dodecahydroindeno[4,5-h]isochromen-7-one
Pharmacological roles (ChEBI): androgen, anabolic agent.
Also known as: Anavar, Lonavar, NSC-67068, Oxandrin, Oxandrolona, Oxandrolone, Oxandrolone ciii, Provitar, SC 11585, SC-11585, Vasorome, OXANDROLONE
Patent coverage: 1,431 distinct patent families (5,232 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Androgen receptor.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 2 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| AR | 9.09 | IC50 | 0.81 | nM | CHEMBL_ACT_24775610 |
| AR | 7.21 | Ki | 62 | nM | CHEMBL_ACT_24824110 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.
| Disease (in trials) | Phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 3 | MONDO:0005070 | EFO:0000616 |
| decubitus ulcer | 3 | MONDO:0004646 | EFO:0007067 |
| Turner syndrome | 3 | MONDO:0019499 | MONDO:0019499 |
| injury | 3 | MONDO:0021178 | EFO:0000546 |
| Klinefelter syndrome | 2 | MONDO:0006823 | EFO:1001006 |
| rotator cuff syndrome | 2 | MONDO:0007028 | EFO:1001250 |
| burn | 2 | MONDO:0043519 | EFO:0009516 |
| Fanconi anemia | 1 | MONDO:0019391 | MONDO:0019391 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 20.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE1 | 4 |
| PHASE3 | 3 |
| Not specified | 3 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 2 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00006167 | PHASE4 | COMPLETED | Nutrition Intervention in AIDS Wasting |
| NCT05893069 | PHASE4 | SUSPENDED | Oxandrolone Multiligament Knee |
| NCT00070148 | PHASE3 | COMPLETED | Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer |
| NCT00101361 | PHASE3 | TERMINATED | Oxandrolone to Heal Pressure Ulcers |
| NCT00673309 | PHASE2/PHASE3 | COMPLETED | Assessment of Mechanisms of Improved Wound Healing |
| NCT00675714 | PHASE2/PHASE3 | TERMINATED | Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation |
| NCT05516849 | PHASE3 | WITHDRAWN | Placebo Versus Oxandrolone Supplementation in Trauma |
| NCT06974526 | PHASE2 | RECRUITING | Subdermal Implant-bioabsorbable Oxandrolone Pellet For Rehabilitation Following Anterior Cruciate Ligament (ACL) Surgical Reconstruction |
| NCT00001343 | PHASE2 | COMPLETED | The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome |
| NCT00004275 | PHASE2 | COMPLETED | Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner’s Syndrome |
| NCT00348946 | PHASE2 | COMPLETED | Androgen Effect on Klinefelter Syndrome Motor Outcome |
| NCT02047552 | PHASE2 | WITHDRAWN | RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone |
| NCT04090697 | PHASE1/PHASE2 | TERMINATED | Use of Oxandrolone to Promote Growth in Infants With HLHS |
| NCT00243399 | PHASE1 | COMPLETED | Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia |
| NCT00652886 | PHASE1 | COMPLETED | Bioavailability Study of Oxandrolone Tablets Under Fasting Conditions |
| NCT01048632 | PHASE1 | COMPLETED | Pilot Study of the Safety and Efficacy of Oxandrolone in the Prevention and Treatment of Malnutrition in Infants |
| NCT03218631 | PHASE1 | COMPLETED | Oxandrolone in Healthy Adults: A Relative Bioavailability Study |
| NCT00027391 | Not specified | COMPLETED | Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD) |
| NCT00223769 | Not specified | COMPLETED | The Use of Anabolic Steroids to Improve Function After Spinal Cord Injury |
| NCT03091075 | Not specified | TERMINATED | Oxandrolone Rotator Cuff Trial |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- In clinical trials for: neoplasm, decubitus ulcer, Turner syndrome, injury, Klinefelter syndrome, rotator cuff syndrome, burn